High‐dose ecabet sodium improves the eradication rate of Helicobacter pylori in dual therapy with lansoprazole and amoxicillin

• Published in: Alimentary pharmacology & therapeutics Vol. 14; no. 11; pp. 1523 - 1527
• Main Authors: Kagaya, H., Kato, M., Komatsu, Y., Mizushima, T., Sukegawa, M., Nishikawa, K., Hokari, K., Takeda, H., Sugiyama, T., Asaka, M.
• Format: Journal Article
• Language: English
• Published: Oxford UK Blackwell Science Ltd 01.11.2000; Blackwell
• Subjects: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin - administration & dosage; Amoxicillin - adverse effects; Amoxicillin - therapeutic use; Anti-Ulcer Agents - administration & dosage; Anti-Ulcer Agents - therapeutic use; Biological and medical sciences; Digestive system; Diterpenes - administration & dosage; Diterpenes - therapeutic use; Diterpenes, Abietane; Drug Therapy, Combination; Female; Helicobacter Infections - drug therapy; Helicobacter pylori; Humans; Lansoprazole; Male; Medical sciences; Middle Aged; Omeprazole - administration & dosage; Omeprazole - adverse effects; Omeprazole - analogs & derivatives; Omeprazole - therapeutic use; Penicillins - therapeutic use; Pharmacology. Drug treatments; Single-Blind Method; Treatment Outcome; Spirillaceae; Antiulcer agent; Eradication; Proton pump inhibitor; Penicillin derivatives; Ecabet; Helicobacter pylori; Bacteria; Gastric disease; Human; Drug combination; Spirillales; β-Lactams; Gastritis; Infection; Antibiotic; Chemotherapy; Chronic; Treatment; Benzimidazole derivatives; Amoxicillin; Bacteriosis; Digestive diseases; Antibacterial agent; Lansoprazole
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1046/j.1365-2036.2000.00852.x

Aim: The additive effect of ecabet sodium in combination with dual therapy on Helicobacter pylori eradication was evaluated. Methods: H. pylori‐positive chronic gastritis patients were randomly assigned to one of the following three groups and medicated for 2 weeks. Group LA: dual therapy (lansoprazole 30 mg o.d. plus amoxicillin 750 mg b.d.). Group LA1E: dual therapy plus ecabet sodium (1 g b.d.). Group LA2E: dual therapy plus ecabet sodium (2 g b.d.). Patients were evaluated 4 weeks after the cessation of treatment by culture and 13C‐urea breath test. Results: Seventy‐one patients (mean age, 56.6 years; range, 26–79 years; 40 males, 31 females) were enrolled in this prospective, single‐blind study, and 68 completed the protocol. The eradication rates per protocol patient were 43% in group LA, 62% in group LA1E, and 79% in group LA2E, and those on the intention‐to‐treat basis were 42% in group LA, 57% in group LA1E and 79% in group LA2E. The eradication rate in group LA2E was significantly higher than group LA (P=0.032 in per protocol, P=0.022 in intention‐to‐treat). Adverse effects were observed in 10 patients in this study. There were no severe adverse effects caused by ecabet sodium. Conclusion: High‐dose ecabet sodium increases eradication rates of H. pylori in dual therapy with lansoprazole and amoxicillin.